Kymera Therapeutics completed enrollment in its KT-621 Phase 2b trial for atopic dermatitis six months early, moving the expected data readout to year-end 2026 and planning Phase 3 trials by mid-2027. The company also continues trials for asthma and other programs, with strong financials including $1.5 billion in cash to fund operations into 2029. These advances highlight Kymera's progress in developing oral therapies for immunological diseases, aiming to address significant treatment gaps. Upcoming data releases and trial initiations position Kymera for growth and potential new treatment options for patients.
Gamehaus Holdings Inc. announced a 20.8% revenue decline to $24.3 million in Q4 2026, driven by reduced user acquisition spending and marketing adjustments. Despite lower revenue, net income fell 38.2% to $0.9 million, while operating costs decreased...
OS Therapies announced that their OST-HER2 immunotherapy achieved a 71.2% three-year overall survival rate in a Phase 2b trial for metastatic osteosarcoma, significantly higher than the 45.8% survival in historical controls (p=0.002). This promising ...
Waterdrop Inc. posted strong Q2 2026 results with net operating revenue up 72.8% year-over-year to RMB1.45 billion (US$213.4 million), driven by an 80.5% increase in insurance-related income. Operating profit rose 14.3% year-over-year to RMB111.3 mil...
Morrisons has partnered with Instaleap, a technology company under Instacart, to enhance its ecommerce operations by streamlining marketplace orders and improving in-store fulfillment. Instaleap's technology integrates orders from platforms like Uber...
First Tellurium Corp. has submitted national phase patent filings for PyroDelta Energy's innovative tellurium-based thermoelectric technology in key regions including Canada, China, Europe, Japan, South Korea, and the US. This move strengthens PyroDe...
